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Abstract
Background: Many studies have evaluated methicillin-resistant Staphylococcus aureus (MRSA) infections during single
hospitalizations and subsequent readmissions to the same institution. None have assessed the comprehensive burden of
MRSA infection in the period after hospital discharge while accounting for healthcare utilization across institutions.
Methodology/Principal Findings: We conducted a retrospective cohort study of adult patients insured by Harvard Pilgrim
Health Care who were newly-detected to harbor MRSA between January 1991 and December 2003 at a tertiary care medical
center. We evaluated all MRSA-attributable infections associated with hospitalization in the year following new detection,
regardless of hospital location. Data were collected on comorbidities, healthcare utilization, mortality and MRSA outcomes.
Of 591 newly-detected MRSA carriers, 23% were colonized and 77% were infected upon detection. In the year following
detection, 196 (33%) patients developed 317 discrete and unrelated MRSA infections. The most common infections were
pneumonia (34%), soft tissue (27%), and primary bloodstream (18%) infections. Infections occurred a median of 56 days
post-detection. Of all infections, 26% involved bacteremia, and 17% caused MRSA-attributable death. During the admission
where MRSA was newly-detected, 14% (82/576) developed subsequent infection. Of those surviving to discharge, 24% (114/
482) developed post-discharge infections in the year following detection. Half (99/185, 54%) of post-discharge infections
caused readmission, and most (104/185, 55%) occurred over 90 days post-discharge.
Conclusions/Significance: In high-risk tertiary care patients, newly-detected MRSA carriage confers large risks of infection
and substantial attributable mortality in the year following acquisition. Most infections occur post-discharge, and 18% of
infections associated with readmission occurred in hospitals other than the one where MRSA was newly-detected. Despite
gains in reducing MRSA infections during hospitalization, the risk of MRSA infection among critically and chronically ill
carriers persists after discharge and warrants targeted prevention strategies.
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Introduction
It is well known that MRSA acquisition confers a high risk of
infection during the same hospitalization. Studies performed in the
past twenty years indicate that approximately 11–20% of patients
who newly acquire MRSA develop subsequent infection during
hospitalization [1–2]. These risks are even higher in intensive care
unit (ICU) patients, with 24–27% of colonized patients developing
infection during hospitalization [3–5]. Increased risks have also
been reported in other hospitalized populations such as patients
with chronic ulcers [6].
However, less is known about the long-term risks of MRSA
acquisition. This is important because post-discharge medical care
is often provided through a variety of methods, such as nursing
homes, rehabilitation centers, and home health care services, and
hospital length of stay continues to shorten. Recent data indicate
that over half of hospitalizations in the United States are 3 days or
less [7]. Thus, despite gains in reduction of healthcare-associated
infections during hospital stays [8–9], studies are needed to
evaluate the full burden of MRSA acquisition after hospital
discharge.
The need to understand post-acquisition MRSA risks is
magnified by widespread initiatives to identify MRSA carriers.
As of 2011, fifteen states have enacted legislation involving
screening, reporting, or other laws targeting MRSA carriers [10].
Nevertheless, once MRSA carriers are identified, little is done to
prevent infection in patients harboring MRSA. Most efforts focus
on contact precautions and room isolation to prevent MRSA
transmission to other inpatients [11–12]. Furthermore, limited
data that do exist on long-term risks suggest that once carriers are
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shortly after discharge and remains elevated up to 12–18 months
following discharge [13–14]. Additional data on MRSA sequelae
in high-risk patients may not only enhance targeted interventions
and future studies seeking to mitigate MRSA morbidity and
mortality in this group, but also inform current multi-state
mandates to screen high-risk hospitalized patients.
We sought to assess the risk of subsequent MRSA infection,
hospitalization and death among high-risk inpatients newly-
detected to harbor MRSA at a tertiary hospital to understand
the magnitude of MRSA burden in a sick cohort. To reduce the
complexity of potential differential virulence due to community-
acquired versus hospital-associated MRSA strains, we studied a
cohort during a time period when healthcare-associated MRSA
was the dominant clone at a single institution.
Methods
We conducted a retrospective cohort study to evaluate the
frequency of subsequent MRSA infection and death among
patients newly-detected to harbor MRSA. We identified a cohort
of adult patients insured by Harvard Pilgrim Health Care who
were newly-detected to have a MRSA-positive culture between
January 1, 1991 and December 31, 2003 at Brigham and
Women’s Hospital, a 750-bed tertiary care academic medical
center in Boston, MA. This study period corresponds to a time
window when genetic testing (pulse field gel electrophoresis) was
being performed on a representative sample of hospital MRSA
strains, and nearly all strains were confirmed to be healthcare-
associated clones (Yokoe D. Personal communication). In addition,
nares surveillance testing for MRSA was not routinely performed
during the study period.
Harvard Pilgrim Health Care is a full-service health benefits
company serving patients throughout New England with a
network of over 135 hospitals and 28,000 physicians [15]. Patients
insured by Harvard Pilgrim Health Care were retained in the
cohort if they had no prior evidence of MRSA-positivity based on
microbiology and infection control records at Brigham and
Women’s Hospital. Patients reporting a history of MRSA-
positivity from other institutions were excluded. We assessed the
risk of subsequent MRSA infection and death among these newly-
detected MRSA carriers by evaluating medical records from the
admission in which MRSA was detected plus all subsequent
inpatient medical facilities in the year following discharge. Newly-
detected MRSA carriage represented colonization or infection by
definition. This study was approved by the Institutional Review
Boards of Brigham and Women’s Hospital and Harvard Pilgrim
Health Care.
Description of Procedures
For outcomes, all inpatient admissions in the year following
MRSA detection were identified by date and hospital name, and
discharge summary and microbiologic culture data were request-
ed. If evidence of MRSA-positive cultures was found during
inpatient hospitalizations, full medical records were obtained.
Outpatient MRSA cultures were not assessed. Medical records
were reviewed to identify the source of the MRSA-positive culture
at the time of new detection and determine whether the positive
culture represented colonization or infection based on Centers for
Disease Control and Prevention criteria [16]. All subsequent
MRSA isolates within a one-year period from the time of new
detection were evaluated for evidence of discrete and unrelated
MRSA infection by reviewers experienced in applying Centers for
Disease Control and Prevention criteria for infection detection. All
infection criteria were additionally verified by an infectious
diseases physician. Subsequent MRSA infections were described
according to (1) the number of days between new detection and
the onset of infection, (2) the type of infection, and (3) whether the
infection was associated with MRSA bacteremia. Infection type
was assigned according to the primary source of infection based on
Centers for Disease Control and Prevention criteria [16].
For descriptive purposes, we obtained demographic, comorbid-
ity and healthcare utilization data for all patients from Harvard
Pilgrim Health Care insurance records. Healthcare utilization
included acute hospital admissions, sub-acute hospital admissions,
admissions to an intensive care unit, emergency room visits,
outpatient visits, surgical and non-surgical procedures in the year
before and after MRSA detection. Comorbidities were identified
using diagnoses of heart disease, asthma, diabetes mellitus, end-
stage renal disease, end-stage liver disease, and noncancer
immunocompromised states based on International Classification of
Diseases, Ninth Revision codes from healthcare claims data in the
year prior to MRSA detection. Identified comorbidities were
verified through medical record review. For all patients newly-
detected with MRSA during an inpatient stay, we also determined
their preadmission location, hospital discharge disposition, inten-
sive care unit admission, and length of hospital stay.
We assessed patient characteristics as the proportion of total
patients with the specified attribute. We determined the
proportion of patients who were colonized or infected at the time
of detection and the proportion of patients who developed any
subsequent infection in the year following MRSA detection. We
evaluated all-cause mortality among patients newly-detected with
MRSA using both Harvard Pilgrim Health Care insurer records
and the Massachusetts Mortality File. We also assessed whether
deaths were associated with MRSA infection at the time of
detection or during the year following detection. If deaths were
associated with MRSA, we further determined whether deaths
were attributable to MRSA. Death was deemed to be associated
with MRSA if MRSA bacteremia was found within 7 days of
death or if there was active MRSA infection at the time of death as
previously described [2,14]. Death was additionally deemed to be
attributable to MRSA if the above criteria were met and there was
no alternative cause of death [2,14].
Statistical Methods
Potential predictors of subsequent MRSA infection among
patients newly-detected with MRSA were assessed using x
2 tests.
Variables significant in bivariate testing at a level of a,0.2 were
entered into a logistic regression model. Final model variables
were retained at a=0.05.
Results
We identified 591 patients insured by Harvard Pilgrim Health
Care with an MRSA-positive culture between January 1, 1991 and
December 31, 2003 at the Brigham and Women’s Hospital who
had no prior evidence of MRSA-positivity. In keeping with rising
MRSA prevalence across the U.S., 22% (N=123) of the cohort
was identified from 1991–1995 (N=189), 31% from 1996–1999,
and 47% (N=279) from 2000–2003. Patient characteristics are
summarized in Table 1. The mean age of patients at the time of
new detection was 62 years (median age, 67 years). Most
individuals were inpatients at the time they were newly-detected
with MRSA, and 40% (230/576) had an MRSA-positive culture
within 2 calendar days of admission to Brigham and Women’s
Hospital. The mean length of hospital stay among inpatients was
22 days (median duration, 16 days).
MRSA Infection in the Year following Detection
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138 (23%) were colonized and 453 (77%) were infected at the time
of entry into the cohort. Among those patients who were
colonized, common sources of MRSA colonization included
sputum (53% of patients), nares (24%), and wounds (9%).
Infections at the time of MRSA detection most often included
pneumonia (41% of patients) and skin and soft tissue (19%)
infections, with 18% of detection infections associated with
bacteremia.
Overall, 196 patients (33%) developed 317 discrete and
unrelated infections in the year after detection of MRSA carriage
(Table 2). The mean time to first MRSA infection following new
detection was 68 days (median, 32 days). Most patients
experienced subsequent MRSA pneumonia, skin and soft tissue,
and primary bloodstream infections. Of all 317 subsequent MRSA
infections, 26% were associated with bacteremia. There was no
difference in the risk of subsequent infection by year (x
2=7.48,
p=0.82) of cohort entry. There was also no difference in infection
risk according to whether patients were colonized (42/138, 30%)
or infected (154/453, 34%) at the time of new detection (x
2=6.77,
p=0.47). Among inpatients, the risk of subsequent infection
differed significantly according to whether patients were admitted
from another hospital (40%, 48/120), home (33%, 122/372), or a
rehabilitation or skilled nursing facility (23%, 19/84) (x
2=6.77,
p=0.03).
The risk of subsequent infection during the admission in which
MRSA was newly-detected was 14% (82/576). Among those
surviving to discharge, the risk of post-discharge MRSA infection
was 24% (114/482). These 114 patients had a total of 185 post-
discharge infections. The mean time to first post-discharge MRSA
infection from the time of new detection was 97 days (median, 72
days). Over half (55%, 104/185) of post-discharge MRSA
infections occurred more than 90 days after discharge, and 45
(25%) occurred more than 180 days after discharge. Overall, 21
(11%) post-discharge MRSA infections would have been missed if
surveillance was not extended to hospitals other than the one at
which MRSA detection was first noted. Furthermore, 99 (54%)
were the cause of hospital readmission and an additional 19 (10%)
were present upon hospital readmission. Among post-discharge
MRSA infections associated with hospital readmission, 97 (82%)
were to the same institution in which MRSA was newly-detected.
The distribution of pre- and post-discharge infections among
patients newly-detected to harbor MRSA is shown in Table 2. The
proportions of skin and soft tissue and bone and joint infections
were significantly greater among post-discharge infections com-
pared to pre-discharge infections (p,0.05). In contrast, there was
no difference in the proportion of MRSA infections involving
bacteremia between pre- and post-discharge infections (x
2=0.01,
p=0.92). There was also no difference in the risk of post-discharge
infection according to whether patients were discharged home
(25%, 48/195), to a rehabilitation or skilled nursing facility (23%,
63/274), or to another hospital (23%, 3/13) (x
2=0.17, p=0.92).
The vast majority of patients (85%) were re-hospitalized in the
year following detection with MRSA (Table 3). Among patients
surviving to discharge, 421 (87%) had a total of 732 subsequent
hospitalizations. Over one-fourth of patients surviving to discharge
(27%, 132/482) had a subsequent hospitalization involving an
ICU stay. The mean length of stay among the 99 resultant
hospitalizations due to MRSA was 13 days (median, 9 days).
Within one year of MRSA acquisition, death occurred in 46%
(269/591) of patients. Over one-third of all deaths (35%, 94/269)
were associated with MRSA, and 20% (54/269) were due to
MRSA. This translated into a 9.1% risk of death due to MRSA
among newly-detected carriers in this cohort. Among those
developing MRSA infection, 48% (94/196) died with MRSA
infection, and 28% (54/196) died due to MRSA infection. The
time to death from the time of detection (Figure 1) and discharge
Table 1. Characteristics of Patients at Time of New Detection
with Methicillin-Resistant Staphylococcus aureus (MRSA).
Characteristic
No. (%) of Patients
(N=591)
Male Gender 337 (57%)
Age
18–34 years 28 (5%)
35–44 years 42 (7%)
45–54 years 73 (12%)
55–64 years 125 (21%)
65–74 years 149 (25%)
75–84 years 147 (25%)
$85 years 27 (5%)
Comorbidity
Heart Disease 349 (59%)
Diabetes Mellitus 154 (26%)
Asthma 106 (18%)
Immunocompromised, Noncancer 77 (13%)
End-Stage Renal Disease 41 (7%)
End-Stage Liver Disease 30 (5%)
Healthcare Utilization in Year Prior to MRSA
Detection
*
Any Hospitalization 476 (81%)
Acute Care Hospital 467 (79%)
Intensive Care Unit Stay 183 (31%)
Emergency Department Visit 435 (74%)
Non-Surgical Procedures 409 (69%)
Surgery 357 (60%)
Skilled Nursing Facility or Rehabilitation Stay 229 (39%)
None of the Above 53 (9%)
Outpatient Visit 563 (95%)
Healthcare Location at Time of New Detection
{
Inpatient 576 (97%)
Outpatient 15 (3%)
Pre-Admission Location
{, {
Home 372 (65%)
Rehabilitation Facility 53 (9%)
Skilled Nursing Facility 31 (5%)
Hospital Transfer 120 (21%)
Discharge Disposition
{, {
Home 195 (33%)
Rehabilitation Facility 233 (39%)
Skilled Nursing Facility 41 (7%)
Hospital Transfer 13 (2%)
Deceased
1 94 (16%)
*Not including admission in which MRSA was newly-detected.
{Evaluation for admission where patient was newly-detected with MRSA.
{n=576.
1Deaths refer to all-cause mortality during admission where patient was newly-
detected with MRSA.
doi:10.1371/journal.pone.0024340.t001
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due to MRSA according to whether patients were discharged
home (3%, 5/195), to rehabilitation or skilled nursing facilities
(3%, 7/274), or to another hospital (0%, 0/13) (x
2=0.14,
p=0.93). In comparison, overall annual mortality from Brigham
and Women’s Hospital excluding obstetric patients ranged from
1.2–2.0% during the study period.
In logistic regression modeling, male gender and age ,35 and
$85 years of age were predictive of subsequent infection with
MRSA (Table 4). The only non-surgical procedures significantly
associated with subsequent MRSA infection were central venous
catheterization and bronchoscopy. The initial site of MRSA
detection, initial infection versus colonization, and comorbidities
other than diabetes, end-stage renal disease, and end-stage liver
disease did not impact the risk of MRSA sequelae.
Discussion
To our knowledge, this work represents the first comprehensive
assessment of MRSA infection, hospitalization and death in the
year following acquisition in a high-risk tertiary care population.
In this cohort, we found that one-third of patients developed
subsequent MRSA infection in the year following acquisition. This
risk of MRSA infection is substantially higher than those reported
in prior studies [1–6], including our own work evaluating the risk
of subsequent infection based upon medical care delivered solely at
the same tertiary care center [13–14]. We found that 18% of
MRSA infections associated with readmission would have been
missed if surveillance was only performed at the same institution as
initial detection.
While advances in infection prevention [12] have reduced
MRSA healthcare-associated infections, particularly those associ-
ated with medical catheters [8–9], these results highlight the
substantial burden of MRSA that persists after hospital discharge.
In this study, nearly 60% of MRSA infections in the year following
detection occurred post-discharge. Moreover, the severity of
MRSA infections did not abate after hospital discharge with
one-quarter of infections involving bacteremia in both pre-
discharge and post-discharge periods. These findings provide
important opportunities for prevention of readmission and later
infection. This is particularly important since hospital length-of-
stay continues to decline [7], and increasingly complex medical
care is delivered through home health care services, rehabilitation
centers, and nursing homes.
Notably, the risk of MRSA infection was not constant over the
year following new detection. These data found that infection risk
was highest in the 3 months following detection, remained high
but to a lesser degree in the next 3 months and then plateaued in
the final 6 months of the one-year follow-up. This is consistent
with an elevated risk during peri-hospitalization periods, similar to
what we previously reported in long-term MRSA carriers [14].
This may be explained by surgeries, procedures, or other health-
related events that provide an increased opportunity for invasion,
such as through wound-related, device-related or immunologic
declines associated with the underlying cause of hospital
admission.
We recognize that it is possible, and even likely, that many
patients in our cohort acquired MRSA long before detection.
Indeed, 40% of patients had an MRSA-positive culture within 2
days of hospital admission, and 81% were hospitalized in the year
prior to detection. However, as described above, we believe that
MRSA infection risk among carriers may be more strongly linked
to hospitalization than time from acquisition. This is supported by
the fact that patients do not develop immunity to prior infecting
strains of MRSA [17], and that long-term carriers remain at
significant risk of MRSA infection [14]. Nevertheless, further
research is needed to confirm this belief. Whether or not active
efforts to decolonize high-risk patients - either newly detected or
persistently colonized with MRSA - are able to prevent later
infections is the focus of ongoing clinical trials [18–19].
The patients in this study reflect the case mix of a tertiary care
academic medical center. It further reflects the case mix of patients
who are at risk of MRSA acquisition. The combination of these
two is reflected by the very high all-cause mortality one year after
MRSA detection. While the risks of subsequent MRSA infection
are unlikely to reflect the experience of patients who harbor
MRSA in outpatient settings or community hospitals, it highlights
Table 2. Sources of Methicillin-Resistant Staphylococcus
aureus (MRSA) Infection in Year Following Detection of
Carriage.
No. (%) of Infections
Infection Classification Total Pre-Discharge* Post-Discharge
Total 317 (100%) 132 (100%) 185 (100%)
Pneumonia
{ 109 (34%) 54 (42%) 55 (29%)
Skin and Soft Tissue
{ 84 (27%) 25 (19%) 59 (31%)
Primary Bloodstream 56 (18%) 28 (22%) 28 (15%)
Surgical Site 18 (6%) 9 (7%) 9 (5%)
Bone and Joint
{ 17 (5%) 2 (2%) 15 (8%)
Urinary Tract 10 (3%) 1 (1%) 9 (5%)
Gastrointestinal 7 (2%) 3 (2%) 4 (2%)
Other
{ 16 (5%) 10 (8%) 6 (3%)
Associated Bacteremia 82 (26%) 33 (25%) 49 (26%)
*Include infections occurring among outpatients at the time of new detection.
{Differed significantly (p,0.05) between pre- and post-discharge infections
using chi-square test.
{Includes 6 eye ear, nose, and throat infections, 6 lower respiratory tract
infections, 3 cardiovascular system infections, and 1 central nervous system
infection.
doi:10.1371/journal.pone.0024340.t002
Table 3. Post-Discharge Healthcare Utilization in Year
Following Detection with Methicillin-Resistant Staphylococcus
aureus (MRSA).
Source of Post-Discharge Healthcare
Utilization*
No. (%) of Patients
(N=498)
Any Hospitalization 421 (85%)
Acute Care Hospital 340 (68%)
Intensive Care Unit Stay 132 (27%)
Emergency Department Visit 319 (64%)
Skilled Nursing or Rehabilitation Facility 301 (60%)
Non-Surgical Procedures 285 (57%)
Surgery 243 (49%)
None of the Above 44 (9%)
Outpatient Visit 394 (79%)
*Proportion of inpatients who survived to discharge from admission in which
MRSA was newly-detected. All proportions account for attrition of study
population due to deaths in year following detection of carriage.
doi:10.1371/journal.pone.0024340.t003
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chronically ill. We postulate that this may reflect the risk of MRSA
sequelae not only among tertiary care patient populations, but also
among MRSA-positive inpatients with the identified risk factors of
advanced age, diabetes, renal insufficiency, or decreased albumin,
regardless of hospital type or location. The 33% one-year risk of
Figure 1. Time from new detection of methicillin-resistant Staphylococcus aureus (MRSA) to infection or death.
doi:10.1371/journal.pone.0024340.g001
Figure 2. Time to infection or death following discharge from the hospitalization in which methicillin-resistant Staphylococcus
aureus (MRSA) was newly-detected.
doi:10.1371/journal.pone.0024340.g002
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MRSA is concerning in an aging population with rising
comorbidities. It is also consistent with the invasiveness of this
pathogen. This is not dissimilar to other healthcare-associated
pathogens [20,21] which target high risk groups. One multi-center
study of Clostridium difficile in predominantly tertiary care hospitals
demonstrated a one-month all-cause mortality of 25% and
attributable mortality of 7% [20]. Collectively, our work points
to the need for interventional studies to reduce the large volume of
infections that occur across the continuum of pre-discharge and
post-discharge medical care.
This study has several limitations. As mentioned above, it is
generalizable only to high-risk MRSA carriers or institutions that
care for high-risk patients. In that context, these data may still
underestimate infection risk since outpatient MRSA infections
were not assessed. In addition, this study describes the risk of
subsequent MRSA infections among hospitalized carriers of
healthcare-associated strains (known by representative sampling
of hospital MRSA strains during this study period). Results may
not apply to U.S. hospitals reporting an increasing prevalence of
community-associated MRSA strains during this period [22–24].
As community-associated strains of MRSA become endemic in
healthcare, it remains to be seen whether the spectrum of
nosocomial disease and the risk of subsequent infection differs by
the origin of MRSA clones. Some evidence has already emerged
suggesting that the pathogenesis of community-acquired MRSA
differs from healthcare-associated MRSA [25]. Finally, this 13-
year cohort may be affected by improvements in medical care and
reductions in mortality over the study period. Nevertheless, we
note that the risk of MRSA infection among carriers remained
stable regardless of the year of cohort entry.
In summary, we show that commercially-insured patients from
a tertiary care medical center incur substantial risks of MRSA
morbidity and mortality in the year following detection of carriage.
One in three MRSA carriers developed MRSA infection, and one
in eleven died because of MRSA infection. Nearly 60% of MRSA
sequelae occurred after discharge from the hospitalization in
which MRSA was newly-detected, and readmission due to MRSA
infection was common. These results suggest that preventative
interventions seeking to reduce MRSA morbidity and mortality
should target patients newly-detected with MRSA and perform
post-discharge follow-up across healthcare facilities to account for
the substantial risks observed in the period after hospital discharge.
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Bronchoscopy 1.6 (1.1, 2.5) 0.02
doi:10.1371/journal.pone.0024340.t004
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